Shop by Category

Other Drug Conjugates

Other Drug ConjugatesAt CellMosaic®, we go the extra mile to support our customers' projects. We have completed many exploratory, challenging, and unconventional drug conjugation projects across a wide range of molecular formats.

Examples of unconventional drug conjugates made at CellMosaic®

    • Complex drug conjugates involving three or more molecular components
    • Lipidation of antibodies and antibody fragments
    • PEGylation of proteins and peptides
    • Modification of small-molecule drugs, such as sugar-curcumin conjugates and activated toxin synthesis
    • Bivalent conjugates, including peptide–protein, Fab–protein, Fab–oligo, and BSA–toxin

Case Studies:

Example 1: Preparation of Protein-mAb(AF647)4.5 and Peptide-mAb(AF647)4.5 conjugates. 

Drug conjugates involving three or more types of molecules, such as protein-antibody-dye conjugates, peptide-antibody-dye conjugates, protein-protein-dye conjugates, have been prepared at CellMosaic® for drug assay development. Here, the protein or peptide acts as a delivery vehicle while the antibody or other protein is a therapeutic agent. The dye helps track the delivery of the therapeutic antibody or protein using a fluorescent imaging technique. The fluorescent dyes are first loaded onto the antibody or protein with DOL at the customers' specification. Then we use controlled reaction conditions plus advanced purification techniques to obtain a 1:1 ratio of protein and antibody/protein-dye conjugates. There is minimum aggregation during the conjugation and 10-20% overall recovery yield for such high-quality complex conjugates.

Preparation of Protein-mAb(AF647)4.5 and Peptide-mAb(AF647)4.5 conjugates. 

 

Example 2: Preparation of Protein 1-Protein 2(AF680)3.6 conjugates (Protein 1: delivery protein, Protein 2: a therapeutic fusion protein). 

Preparation of Protein 1-Protein 2(AF680)3.6 conjugates (Protein 1: delivery protein, Protein 2: a therapeutic fusion protein).  

 

Example 3: Preparation of Lipid-PEG-Fab' conjugate at CellMosaic®. We developed a process to produce F(ab')2 from IgG in high yield (over 50% recovery after purification). The Fab' fragment is highly unstable and presents a challenge during conjugation and storage. 

Preparation of Lipid-PEG-Fab' conjugate at CellMosaic®. We developed a process to produce F(ab')2 from IgG in high yield (over 50% recovery after purification). The Fab' fragment is highly unstable and presents a challenge during conjugation and storage

 

There are no products listed under this category.